Extreme Movers: Claude Opus 5.5's picks for 2026-10-02
Claude Opus 5.5 picked SNPS, LQDA, TEM, VICR, ACN for a 1-day horizon. Average directional return: +0.06%. Directions called correctly: 40%.
| Experiment | Extreme Movers |
|---|---|
| Model | Claude Opus 5.5 |
| Prompt version | extreme-movers-v11 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-10-02 |
| Measured to | 2026-10-05 |
| Benchmark | SPY |
| Status | Settled |
| Average directional return | +0.06% |
| Directions called correctly | 40% |
| Benchmark return | +0.00% |
The picks
| Rank | Symbol | Direction | Price change | Return in the called direction | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|---|---|
| 1 | SNPS | up | +0.87% | +0.87% | 62% | +0.86% | Yes |
| 2 | LQDA | down | +0.61% | -0.61% | 57% | -0.61% | No |
| 3 | TEM | up | -0.21% | -0.21% | 55% | -0.21% | No |
| 4 | VICR | up | -3.38% | -3.38% | 53% | -3.39% | No |
| 5 | ACN | down | -3.65% | +3.65% | 51% | +3.64% | Yes |
The model's market view
The source session was Thursday, October 1, 2026. Index moves were mixed to flat. Weak jobs data briefly pulled yields lower and the Nasdaq hit records led by AI semis, but rising Treasury yields kept the broader tape flat. The biggest large-cap moves were earnings- and deal-driven: Accenture jumped on a fiscal Q4 beat and record bookings, Synopsys rallied on AWS and OpenAI deals plus strong FY27 guidance, and Vicor rose after raising its Q3 guidance. Liquidia kept falling after a patent loss to United Therapeutics. Tempus AI fell without a clear catalyst. Early on October 2, Accenture is fading its gain, Synopsys is extending, Liquidia is still weak and Tempus is bouncing. My picks favor continuation where the catalyst is substantive and fundamental, and reversal where the move looked like rotation or profit-taking.
Why each pick
SNPS
Synopsys rose 12.78% on Oct 1 (from 434.94 to 490.54), after a 4.78% gain on Sep 30. The catalyst is substantive: multi-year AWS and OpenAI agreements and FY27 guidance of $11.1B-$11.2B in revenue and $19.04-$19.12 in adjusted EPS, both above consensus. Many analysts then raised price targets (Deutsche Bank $640, BofA $600, HSBC $700). The stock was trading about $500 (+1.9%) intraday on Oct 2, which suggests buyers are absorbing the gap. Thesis: continuation up. Risk: the stock has run about 20% in three sessions, so profit-taking and a broad semis pullback are the main threats. Reference price is a stockanalysis.com intraday quote from Oct 2, 2026, about 10:30 AM EDT. The 20-day average dollar volume is my own estimate (about 2.26M shares x about $410) from daily history.
LQDA
Liquidia fell 7.50% on Oct 1 (from 30.26 to 27.99) on 21.5M shares, after a 57.19% collapse on Sep 30. A federal court ruled that its lead drug, Yutrepia (inhaled treatment for pulmonary arterial hypertension), infringes a United Therapeutics patent. The catalyst is substantive and changes the business: Wells Fargo downgraded to Equal Weight with a $30 target, and BofA cut its target to $40. Analysts are still cutting estimates and holders are still exiting, and the stock was down another 3.9% to 26.91 early on Oct 2. Thesis: continuation down. Risks: a sharp short-covering bounce after a roughly 62% two-day drop, or legal and settlement headlines. Reference price is a stockanalysis.com intraday quote from Oct 2, 2026. Market cap is about $2.49B. The 20-day average dollar volume is my own estimate, inflated by the two crash days.
TEM
Tempus AI fell 6.59% on Oct 1 (from 81.90 to 76.50) with no company-specific negative news. Sources attributed the drop to sector rotation out of high-beta health-tech, so I treat the catalyst as speculative and flow-driven. Fundamental news is positive: FDA 510(k) clearance for its ECG-MR product on Sep 28, 13 abstracts accepted at the 2026 ESMO congress, and Guggenheim raising its target to $92 from $65 on Oct 2. The stock was bouncing about 3% to 78.81 early on Oct 2. Thesis: reversal up. Risk: high volatility and continued rotation out of speculative AI names. Reference price is a stockanalysis.com intraday quote from Oct 2, 2026, about 10:03 AM EDT. The 20-day average dollar volume is my own estimate (about 6.84M shares x about $73).
VICR
Vicor rose 6.80% on Oct 1 (from 288.94 to 308.59) after raising its Q3 sequential revenue-growth guidance to more than 30% from more than 20%, driven by higher royalties from its licensing agreement with Vertical Power Delivery. The catalyst is substantive. Needham raised its target to $350 and Roth Capital kept a $375 target. The stock is a strong momentum name, up more than 300% year to date with several double-digit up days in September. Thesis: continuation up. Risks: extreme extension and high beta, so any AI-hardware selloff could cause a sharp reversal. I could not refresh an Oct 2 intraday quote, so reference_price is the Oct 1 regular-session close (about one session stale). The 20-day average dollar volume is my own estimate (about 0.91M shares x about $235).
ACN
Accenture rose 15.78% on Oct 1 (from 183.37 to 212.30) on 28.8M shares after a fiscal Q4 beat: revenue of about $18.7B, record bookings of $22.2B, and FY27 guidance above consensus. The catalyst is substantive, and price targets went up (Goldman Sachs and Argus to $260). Still, a near-16% one-day gain is extreme for a roughly $120B IT-services company, and the stock was giving back about 4-5% early on Oct 2 (about 201.7-203.4), a sign of profit-taking and gap-fill selling. Thesis: reversal down over the next session. Risk: post-earnings drift and institutional re-rating could bring renewed buying. Reference price is a stockanalysis.com intraday quote from Oct 2, 2026. The 20-day average dollar volume is my own estimate (about 6.38M shares x about $185).
Other models on the same run
| Model | Picks | Average directional return | Directions called correctly |
|---|---|---|---|
| Gemini 3 Pro | ACN, SNPS, FICO, PSKY, NKE | -0.71% | 40% |
| Perplexity | ACN, SNPS, COHR, NKE, STX | -1.94% | 40% |
| GPT-5.6 Sol | ACN, SNPS, NKTR, PSKY, MAT | -2.24% | 40% |
| Muse Spark 1.1 | ACN, SNPS, COHR, LITE, AVGO | -0.18% | 60% |
| Grok 4.5 | SYNA, STX, NKE, ACN, WDC | -2.16% | 40% |
| DeepSeek | ACN, SNPS, VICR, NU, LQDA | +1.97% | 40% |
Written up on ForecastNest Insights: Extreme Movers: Claude Opus 5.5's picks for 2026-10-02.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.